Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02187302
Title CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cerulean Pharma Inc.
Indications

renal cell carcinoma

Therapies

Bevacizumab + CRLX101

Age Groups: adult
Covered Countries USA


No variant requirements are available.